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Staphylococcus aureus plays a majorrole as abacterial pathogen in human medicine,
causing diseases that range from superficial skin and wound to systemic nosocomial
infections. The majority ofS. aureus strains produces a toxin, a proteinaceous exo-
toxin whose hemolytic, dermonecrotic, and lethal properties have long been known
(1-6). The toxin is secreted as a single-chained, nonglycosylated polypeptide with
a Mr of 3.4 x 104 (7, 8). The protein spontaneously binds to lipid monolayers and
bilayers (9-14), producing functional transmembrane pores that have been sized to
1.5-2 .0-nm diameters (15-18). The majority of pores formed at high toxin concen-
trations (20 ug/ml) is visible in the electron microscope as circularized rings with
central pores of -2 nm in diameter. The rings have been isolated, and molecular
weight determinations indicate that they represent hexamers of the native toxin (7) .
We have proposed that transmembrane leakiness is due to embedment of these ring
structures in the bilayer, with molecular flux occurring through the central channels
(15, 19). Pore formation is dissectable into two steps (20, 21). Toxin monomers first
bind to the bilayer without invoking bilayer leakiness. Membrane-bound monomers
then laterally diffuse and associate to form non-covalently bonded oligomers that
generate the pores. When toxin pores form in membranes of nucleated cells, they
may elicit detrimental secondary effects by serving as nonphysiologic calcium channels,
influx of this cation triggering diverse reactions, including release of potent lipid
mediators originating from the arachidonate cascade (22-24).
That a toxin represents an important factor of staphylococcal pathogenicity has
been clearly established in several models of animal infections through the use of
genetically engineered bacterial strains deleted of an active a toxin gene (25-27).
Whether the toxin is pathogenetically relevant in human disease, however, is a matter
ofcontinuing debate. Doubts surrounding this issue originate from two main findings.
First, whereas 6070 hemolysis ofwashed rabbit erythrocytes is effected by -75 ng/ml
a toxin, -100-fold concentrations are required to effect similar lysis of human cells
(4-6, 13). The general consensus is that human cells display a natural resistance
towards toxin attack. The reason for the wide inter-species variations in suscepti-
bility towards a toxin is unknown but does not seem to be due to the presence or
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absence of high-affinity binding sites on the respective target cells (20, 21). Second,
low-density lipoprotein (28) and neutralizing antibodies present in plasma ofall healthy
human individuals inactivate a substantial fraction of a toxin in vitro. These inac-
tivating mechanisms presumably further raise the concentration threshold required
for effective toxin attack, and it is most unlikely that such high toxin levels will ever
be encountered during infections in the human organism.
The aforegoing arguments rest on the validity of two general assumptions. First,
the noted natural resistance of human erythrocytes to a toxin must be exhibited by
other human cells. Second, toxinneutralization by plasma components, usually tested
and quantified after their preincubation with toxin in vitro, must be similarly effec-
tive under natural conditions, and protection afforded by these components must
not be restricted to specific cell species.
In 1964, Siegel and Cohen (29) presented suggestive evidence that human platelets
may be more susceptible towards attack by a toxin than erythrocytes. These authors
described shape changes undergone by isolated platelets upon incubation with a crude
toxin preparation. They also noted that such platelets apparently released (a) pro-
coagulatory factor(s) parallel to leaking K+ and nicotinamide adenine dinneleotide
in the absence of overt cell lysis. At the same time, Bernheimer and Schwartz (30)
reported that a toxin induced a dramatic decrease in turbidity of rabbit platelet sus-
pensions that, however, appeared to be due to frank platelet lysis. Since the time
of these interesting observations, no further detailed studies have been conducted
on the interaction of a toxin with human platelets.
In the present communication, we report that human platelets indeed differ from
human erythrocytes in being as sensitive towards a toxin attack as rabbit erythro-
cytes. It will be demonstrated that neutralizing antibodies to a toxin, although fully
effective when assayed by standard procedures, fail to protect platelets against even
low levels of a toxin in human blood. a toxin becomes the first bacterial cytolysin
recognized to activate human platelets and promote blood coagulation in subcyto-
lytic concentrations, processes that bear high potential relevance in staphylococcal
infections.
Materials and Methods
Monomeric a toxin was recovered from a Sephacryl S-300 column after chromatography
of a partially purified lyophilized toxin preparation (kindly donated by Behringwerke, Mar-
burg, FRG), as described (15). Additionally, the toxin was purified in our laboratory from
culture supernatants of S. aureus Wood 46 following a protocol that is to be reported elsewhere.
These toxin preparations contained only very few residual contaminants that were approxi-
mated to represent <1-2°lo of total protein according to densitometric analyses of SDS-
polyacrylamide gel stained with Coomassie Blue (Fig. 1). The toxin solutions with a protein
content of 0.5-0.8 mg/ml were stored in aliquots at -20°C.
Hemolysis Assays.
￿
Whole citrated human blood from healthy adults, or washed erythro-
cytes suspended to 50% hematocrit in PBS, were treated with 1 vol ofa toxin doubly diluted
in PBS. Hemolysis was quantified by measuring hemoglobin absorbance at 412 nm in the
supernatant after 60 min at 37°C.
Whole Blood Samples.
￿
Blood was drawn in citrate, heparin (3 U/ml final concentration),
or EDTA (10 mM, final concentration) and held at room temperature until used.
Platelet Preparations.
￿
Platelet-rich plasma (PRP)' was obtained from five healthy adults
' Abbreviations used in this paper: PF-4, platelet factor 4; PPP, platelet-poor plasma; PRP, platelet-rich
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FIGURE 1 .
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SDS-PAGE of purified a toxin (B) and calibration proteins
(A) . 20 ~Ig of protein were applied to gel B . The calibration proteins
(Serva, Heidelberg, Federal Republic of Germany) and their molecular
weights were : (a) phosphorylase b (9 .4 x 104 ) ; (6) BSA (6 .7 x 10 4 ) ; (c)
OVA (4 .3 x 104) ; (d) carbonic anhydrase (3 x 10 4 ) ; (e) lactalbumin
(20,100). Gels were stained with Coomassie Brilliant Blue .
through centrifugation of citrated blood samples (20-30 ml) at 200 g for 20 min (Minifuge,
Heraeus Christ, Osterode, FRG) at 21°C . The PRP was carefully aspirated, the pH adjusted
to 7.3 with 0.2 M maleic acid, and preparations were gently agitated at 12 °C in a water bath .
Platelet-poor plasma (PPP) was obtained by recentrifuging PRP at 5,600 g for 10 min, fol-
lowed by four 2-min centrifugations ofthe supernatants at 8,000 g in a table top Eppendorf
centrifuge . Platelet counts in PRP ranged between 2.3 and 7.5 x 105/gl ; PPP contained <100
platelets/gl .
Platelets were isolated from PRP according to Mustard et al . (31) . The final platelet sus-
pensions contained no white blood cells . The washed platelets were suspended in 135 mM
NaCl, 2.7 mM KCI, 12 mM NaHC03, 0.3 mM NaH2PO 4 , 0.35% (wt/vol) human serum
albumin, 0.1% (wt/vol) glucose, and were held at room temperature until used .
Measurements ofPlatelet Aggregation andATP Release.
￿
These measurements were conducted
simultaneously in a Lumi-Aggro-Meter (model 400, Chrono-LogCorp., Coulter Electronics,
Krefeld, FRG ; reference 32) . The aggregometer was equipped with a double-channel Omni-
ScribeRII recorder (Coulter Electronics) for continuous recordings of optical measurements .
ATP was assayed by the firefly method using luciferin/luciferase reagent (50 gl reagent per
assay ; Chrono-Lume #395 from Chrono-LogCorp. ; reference 33) . Experiments were con-
ducted with PRP and with washed platelets . PRP samples (0.4 ml) were preincubated at37°C
for 3 min before aggregation assays . Washed platelet suspensions were supplemented with
2 mM Ca2 ', 1 MM
Mg2', and 30 gg/ml fibrinogen (Kabi Vitrum, Munich, FRG) before
addition of the stimuli .
Measurements ofPlatelet Factor 4 (PF-4) Release.
￿
These measurements were conducted using
a commercially available ELISA (Enzygnost PF4, Behringwerke) . Experiments were con-
ducted with whole blood samples and isolated platelets. In the latter, platelet suspensions
were supplemented with 5 mM Ca2' before addition of a toxin . After an incubation for 20
min at 37°C, samples were centrifuged at 2,000 g (60 min, 4°C) to sediment the platelets,
and PF-4 was determined in the supernatants .
Determination ofLactate Dehydrogenese (LDH).
￿
LDH was determined with the use of a com-
mercially available test (aca-LDHTestpack, DuPont Lab ., Bad Nauheim, FRG) .
Measurements of Clot Time .
￿
These were performed with the use of a Mecrolab Clottimer
202 A (Heller Laboratories, Santa Rosa, CA) . Experiments were conducted at 37°C with530
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citrated whole blood, citrated PRP, PPP, and mixtures ofPRP and PPP containing varying
platelet concentrations . Clot reactions were initiated through addition of 12 mM Ca plus
or minus a toxin to the samples .
Assessment of Platelet-bound Toxin.
￿
Washed platelets were suspended to 7-9 x 105 platelets/RI
and treated with a toxin in the absence ofCa and fibrinogen for 20 min, 37°C . The toxin-
treated platelets were washed thrice in PBS by centrifugation at 8,800 g for 3 min in a table
top Heraeus Christ BiofugeA centrifuge. The platelets were solubilized either through addi-
tion of 50 mM Triton X-100 for quantification of bound monomers, or by boiling for 30 s
in 70mM SDS for determination of total bound toxin . The specificity and performance of
the sandwich ELISA used has previously been described in detail (20, 21) .
Other Reagents .
￿
ADP was obtained from Boehringer (Mannheim, FRG) . Fibronogen was
from Kabi Vitrum (Munich, FRG) . mAb a4C1 against a toxin has been described (20) . An-
other mAb, 4G3, was produced that does not inhibit toxin binding but inhibits lateral aggre-
gation and oligomer formation in the cell membrane (Hugo, F, B . Eberspacher, and S . Bhakdi,
unpublished data) . Indomethacin was purchased fromMSD Sharp and Dome (Munich, FRG)
and the thromboxane receptor antagonist BM 13 177 was a gift from Boehringer (Mann-
heim, FRG) . Commercial human Ig preparations were from Sandoz (SandoglobinR ; Basel,
Switzerland) and Behringwerke (BeriglobinR ; Marburg, FRG) .
Results
Hemolysis ofHumanErythrocytes by a Toxin .
￿
As known from the early literature (4),
washed human erythrocytes are lysed only by high concentrations of a toxin, 60%
lysis of a 50% cell suspension occurring at -12-15 ug/ml a toxin . In the presence
ofplasma proteins, onset of hemolysis was markedly retarded and comparablehemo-
lysis of cells in whole citrated blood occurred at toxin concentrations of -50 gg/ml
(Fig . 2) . Hemolysis in whole blood was always nil at 5 pg/ml and 0 to<2% at 10 ftg/ml
of a toxin . These results reiterate the intrinsic high resistance of human erythro-
cytes towards toxin attack and show that plasma factors, presumably antibodies and
low-density lipoprotein, further effectively protect red cells against a toxin in whole
blood.
Release of PF-4 Invoked by a Toxin in Whole Blood .
￿
In sharp contrast to the resis-
tance of erythrocytes towards lytic toxin action, human platelets present in citrated
or heparinized whole blood responded to nonhemolytic levels of a toxin by release
of granular constituents . Fig . 3 depicts the release of PF4 in blood of one donor
anticoagulated with citrate, heparin, or EDTA . Essentially, the same patterns were
reproduced with two other donors . The background levels ofPF4 measured in con-
trols not treated with the toxin were somewhat high (200-600 ng/ml) due to the
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FIGURE 2 .
￿
Lysis ofhuman erythrocytes by staphylococcal a toxin.
(A) 50% suspension of washed cells in PBS; (" ) whole citrated
blood .BHAKDI ET AL .
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FIGURE 3 .
￿
Release ofPF4from platelets in (10 mM) whole human
blood anticoagulatedwith heparin (3 U/ml), citrate (10mM), orEDTA
(10 mM) upon treatment with subhemolytic doses of staphylococcal
a toxin. PF-4 was quantified in the supernatants after a20-min incu-
bation with the toxin .
incubation of samples at 37°C . PF-4 release was noted at toxin levels ofN1 ug/ml,
and plateaued at 2.5-5.0 gg/ml toxin in heparin and citrated blood. Unexpectedly,
less PF4 was measurable in supernatants of platelets treated with 12 .5 gg/ml toxin
in the presence of citrate. The presence of 10mM EDTA abolished the effects evoked
by 2.5-12.5 leg/ml toxin, whereby PF-4 measured at 12.5 gg/ml again presented the
lowest values . At levels of ti 1 ug/ml, atoxin appeared to induce release of very small
amounts of PF4, even in the presence of EDTA .
a Toxin Induces Aggregation ofPlateletsandATPRelease in PRP .
￿
In classical aggrega-
tion tests, a toxin in the same concentration range of 1-2.5 gg/ml induced platelet
aggregation andATP release in PRP from five healthy individuals . Fig . 4A depicts
the classical platelet response to an ADP stimulus (34) ; shape change is followed
first, by primary aggregation withoutATP release, and then by secondary, irrevers-
ible aggregationthat is paralleledbyATPliberation (35). Fig . 4B depictsthe platelet
response in one donor evoked by 2 .5 gg/ml a toxin. A virtually identical aggrega-
tion pattern was noted after a short lagphase of -30 s. However, ATP release oc-
curred earlier than with ADP, coinciding with the commencement of the aggrega-
tion response . ATP releasewas also always enhanced compared with theADP response .
At 1 gg/ml toxin, the lag-phase was prolonged to 60-80 s, and the aggregation rate
was slower. The simultaneous commencement of aggregation and ATP release is
well recognizable at this thresholdtoxin concentration (Fig . 4 C) . Aggregationalways
appeared irreversible even at low toxin levels . Toxin concentrations of<1 gg/ml usually
did not elicit aggregation or ATP release (maximum time of observation: 5 min) .
With one donor, however, a platelet response similar to that shown in Fig . 4 C was
observed with0.5 gg/ml toxin . With anotherdonor, the platelet response commenced
at 2.5 ttg/ml rather than at 1 gg/ml toxin . These differences are presently attributed
to the varying levels of antitoxin antibodies and low density lipoprotein in the in-
dividual plasma samples .
Release of PF-4 andATP Is not Due to Platelet Lysis.
￿
Aliquots of PRP containing
3 x 105 platelets/g1 were incubated with 0-12 .5 wg/ml a toxin for 15 min at 37°C .
After removal of platelets by centrifugation, LDH was determined in the superna-
tants . A sonicatedPRP sample served as positive control . Whereas aconcentration
of500U/mlLDH was measured in the latter, all a toxin-treated samples presented532
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FIGURE 4 .
￿
Recordings ofOD changes due to platelet aggregation (upper traces) and ofATP re-
lease (lower traces) in platelet-rich plasma induced by ADP (A) and staphylococcal a toxin (B and
C) . 2 gM ATPwasadded as a calibration to the sample at the end of the experiment inB. Chart
speed : two and a half columns correspond to 1 min . The traces representing ATP precede OD
traces by one and a quarter columns.
concentrations of 110 U/ml, identical to the LDH level of the saline control . Hence,
a toxin applied in the given doses does not lyse human platelets in PRP
Neutralizing mAbs Impart only Partial Protection ofPlatelets against Toxin Action.
￿
Two
mAbs that were capable of neutralizing hemolytic toxin effects were used . ThemAb
a4C1 binds to native toxin monomers and prevents theirbinding to target cells . mAb
4G3 does not inhibittoxin binding, but blocks oligomerisation ofmembrane-bound
toxin monomers . Both antibodies suppressed release of PF4 from platelets in
heparinized whole blood when preincubated with a toxin before its administration
(Fig . 5A) . As controls, six purified IgG murine mAbs directed against streptolysin-
O or terminal C5b-9 complement complexes(for review, see reference 19)were used
at similar concentrations . These irrelevant antibodies did not suppress the actionA 2.4
2.0
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FIGURE 5.
￿
(A)Inhibition oftoxin-induced
platelet activation by mAbs. Heparinized
whole bloodwas treatedwith a toxin(A),
toxin preincubated (3 min) with mAb
a4C1 (/), or mAb4133 (0), andthe con-
centrations of PF4 were subsequently
measured in the cell-free supernatants.
Themolarratios oftoxinto antibodywere
N1 :2 in all cases. (B) Specificity of toxin
neutralization by mAbs. atoxin waspre-
incubated with saline (b); with neutralizing
mAb a4C1 (c; molarratio of toxin to an-
tibody, 1:3);or with oneof four irrelevant
mAbs (d-g) for 2 min, 22°C, and then
added to heparinized blood. The final
toxinconcentration was 2.5 pg/ml. After
20 minat 37°C, PF-4 wasdetermined in
the cell-freesupernatant. (a)Control with-
out atoxin. Similar results were obtained
in anotherexperiment using two further
irrelevant mAbs (not shown).
of atoxinon platelets (Fig. 5 B). The neutralizing capacity ofboth neutralizing mAbs
was, however, overrun if the antibodies were not preincubated with toxin. In the
aggregation experiment of Fig. 6, mAb a4C1 wasused at a concentration of 10 ug/ml.
If preincubated with 2.5 gg/ml toxin for 2 min at 22'C, the antibody effected total
neutralization, and no platelet aggregationwas noted (molar ratio oftoxin:antibody,
N1 :1). Upon posttreatmentwith an additional 2.5 gg/ml toxin, aggregation ensued
(Fig. 6 A). If antibodies were applied simultaneously with the toxin, however, pro-
tracted aggregation occurred (Fig. 6 B) after a slightly prolonged lag-phase. If given
30 s after toxin application, the mAb was totally incapable of preventing platelet
aggregation (Fig. 6 C. These results demonstrate that a toxin binds rapidly to
platelets, and neutralizing antibodies are rather ineffective in protecting platelets
against toxin action. At the same time, these results show that the noted platelet
responses are due to binding and oligomerisation of a toxin, and not to acontaminant
possibly contained in the toxin preparation. Preincubation of a toxin with any of
the six irrelevant mAbs (molar ratio of toxin to antibody, ti1:3)failed to affect toxin-
induced aggregation.
Response of Washed Plateletsto ToxinAttack.
￿
Isolated platelets exhibited ayet higher
susceptibility towards a toxin, aggregation, and ATP release already commencing
at toxinlevels of 50-100 ng/ml and always maximal at 0.5-1.0 Erg/ml. Release of PF
4was also noted at theselowtoxinconcentrations. If platelet suspensions were recon-
stituted with preparations ofpooled humanIgs(final IgG concentration: 10 mg/ml),
the toxin levels required to elicit aggregationand ATP release returned to the region
of ti 1-2 wg/ml. These results indicate that human IgGantibodies impart partialpro-
tection against the platelet activation effects of a toxin. However, as noted in whole
blood and PRP, this protection ends at a relatively low threshold concentration in
the range of 1-2 gg/ml a toxin.
Toxin-dependent Platelet Stimulation Bypasses Cyclooxygenase Pathway.
￿
The presence of
50 pM indomethacin (cyclooxygenase inhibitor) or 5 pM BM 13177 (thromboxane
receptor blocker) abrogatedATP release andsecondary platelet aggregation induced534
￿
BACTERIAL EXOTOXIN PROMOTES COAGULATION
FIGURE 6 .
￿
Inhibition of platelet aggregation and ATP release by mAbs . (A) a toxin was prein-
cubated with mAb a4C1 at a molar ratio of 1 :1 (toxin/mAb) for 2 min at 22°C, and then added
to PRP (final toxin concentration in PRP : 2.5 ug/ml) ; no toxin effects were discerned . Addition
of another 2 .5 ug/ml toxin to the sample resulted in platelet aggregation and ATP release. (B)
Toxin and mAb were applied in the same dose as in A simultaneously . In this case, the mAb
could not prevent platelet activation and aggregation. (C) toxin (2 .5 wg/ml) was applied 30 s be-
fore the mAb ; no protective effect of the antibody was observed .
byADP (Fig. 7, A andB) . However, neither inhibitorwasable to influencetheplatelet
response to a toxin (Fig . 7, C and D) . Hence, toxin-induced platelet activation
bypasses the cyclooxygenase pathway (36-38) and is thromboxane independent .
Quantitation of Toxin Binding to Platelets.
￿
Washed platelets were suspended in buffer
without Cat+ and fibrinogen, treated with a toxin, and bound toxin was subse-
quently quantified by ELISA. As shown in Fig . 8, measurable binding ofa toxin
to washed platelets commenced at levels -100 ng/ml and increased with the amount
of toxin offered . The binding exhibited no recognizable saturation and displayedBHAKDI ET AL .
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FIGURE 7 .
￿
Toxin activation of platelets bypasses cyclooxygenase pathway. PRP samples were
given 50 uM indomethacin (A and C) or 5 uM thromboxane receptor blocker BM 13 177 (B
and D) and treated with 2 x 10-5MADP (A and B) or 2.5 wg/ml a toxin (C and D) . ADP-
dependent secondary aggregation and ATP release were blocked by both agents, whereas toxin-
induced effects remained unchanged.
no characteristics of a receptor-ligand interaction ; the total net binding was calcu-
lated to be -10% at all toxin concentrations between 0.5 and 12.5 Pg/ml . A similar
binding behavior was previously noted with rabbit erythrocytes (21). The ELISA
permitted quantitative differentiation between toxin monomers and oligomers . At536
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Quantitation of the binding of a
toxin to isolated human platelets. A suspen-
sion ofplatelets (9 x 105/Wl) was given a toxin
at the depicted finalconcentrations, and plate-
let-bound toxin was quantified by ELISA,
which differentiated between monomeric and
total toxin. Net binding was -1017o of total
toxin offered in each sample, and no satura-
bility ofbinding was observed in the measured
range.
all toxin doses applied, monomers constituted -2 To of total toxin. The number of
oligomerc toxin molecules bound at lowest toxin concentrations (100 ng/ml) was
below thedetection limitofthe ELISA. Assuming that the majorpopulation ofcell-
bound oligomers represented hexamers, we estimate that ATP release and platelet
aggregation commences upon average binding of <10 toxin hexamers, and is max-
imal upon binding of <100 hexamers per platelet (Fig. 8). These results emphasize
the high efficiency of a toxin in activating human platelets.
a Toxin Accelerates Blood Coagulation.
￿
These experiments were conducted with
citrated blood, PRP, and PPP. Clotting was initiated by recalcification in the ab-
sence or presence of a toxin. As shown in Fig. 9, the presence of a toxin dose-
dependently enhanced the rate of clot formation, significant effects already being
noted at 1 lag/ml toxin concentration. Maximal reduction of clot times of N70%
occurred when the toxin was applied to PRP at levels of 2.5-5 ttg/ml. PPP exhibited
no response to a toxin; hence acceleration of clot formation was dependent on the
presence of platelets. Reductions in clot times similar to those observed in normal
PRP (containing 2.3 x 105 platelets/pl) were alreadyobserved in plasma containing
2.3 x 104 platelets/ul, and a clot-enhancing effect of a toxin was noted even at
platelet counts of 1-2 x 103/g1. Similar acceleration in clot formation was observed
upon addition of a toxin to whole citrated blood. The reductions in clot times wereBHAKDl ET AL.
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FIGURE 9
￿
Reduction in clot times of recalcified human plasma by a
toxin. Citrated plasma samples containing the depicted numbers of
platelets (per nanoliter) were given 12 mM Ca2, and a toxin at the given
final concentrations. Marked reductions clot times were noted at toxin
concentrations of 1-2.5 gg/ml, dependent on the presence of platelets in
the plasma sample. No clot indicates lack of clot formation within 900 s.
totally abrogated if a toxin was preincubated with mAb a4C1 (two molecules anti-
body per molecule toxin, 2 min, 22°C) .
Discussion
Unexpected aspects regarding the action and potential pathophysiological rele-
vance of a major bacterial cytolysin in the human organism arise from the present
study. The dogma that human cells are generally insensitive towards staphylococcal
a toxin attack must be rectified. In fact, human platelets exhibit similar suscepti-
bility towards the toxin as rabbit erythrocytes, responding to toxin levels as low as
50 ng/ml. The platelet reaction comprises a classical irreversible aggregation upon
stirring of PRP at 37°C in an aggregometer, paralleled by release of a granule con-
stituents (39-44), documented in the present study through measurements of liber-
ated PF4. Toxin-treated platelets also released ATP, whereby differentiation between
ATP released from the cytosol as opposed to release from dense bodies was not yet
undertaken. Binding of a toxin to platelets is rapid, ensuing within 30-90 s at 37°C.
Elicitation of the platelet reaction requires not only binding of monomers, but also
formation of membrane-bound oligomers, since it can be prevented by preincuba-
tion of toxin with two mAbs, one acting to inhibit toxin binding, the other blocking
toxin oligomerisation . The rapidity and high efficiency of toxin action on platelets
could partially account for the second unexpected finding that neutralizing antibodies
fail to effectively protect platelets against a toxin. In PRP and whole blood, the
threshold concentration required for successful toxin attack is raised in the presence
of human antibodies to only ti 1-2 wg/ml. In contrast, red cell lysis in whole blood
is usually nil even at toxin concentrations of 10 ug/ml. We have found that human
white blood cells display a similar resistance towards a toxin as erythrocytes (un-
published data). Our results thus confirm the suspicion of Siegel and Cohen (29)
that they had "identified a human cell (or cell fragment) highly susceptible to this
agent," and identify platelets as the primary cell targets for a toxin attack in human
blood. The cause for the high susceptibility of platelets compared with other blood538
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cells is unknown . The unsolved enigma regarding the widely differing susceptibility
of various cell targets to toxin attack has recently been discussed in detail (21, 45),
and we have no new data to justify any further speculation at present . The binding
data obtained in this study are very similar to those found for toxin binding to rabbit
erythrocytes and speak against the presence of specific, saturable receptors on the
platelets . As discussed previously (21, 45), we believe that surface properties of the
respective cell target, such as density and orientation of charged groups, are impor-
tant in determining the concentration threshold at which successful toxin attack will
occur. Even when this takes place, overall net toxin binding will be rather ineffective,
and toxin molecules will not be quantitatively taken up by the cell targets . In the
present study (Fig . 8), we estimate that only -10% of toxin offered in solution be-
comes platelet bound, the bulk oftoxin thus remaining available for attack on other
cells . The binding inefficiency of a toxin to rabbit platelets was indeed already noted
by Bernheimer and Schwartz in 1965 (30) . These authors showed that continued
loss of turbidity occurred when several aliquots of rabbit platelets suspensions were
consecutively added to toxin solution .
The precise nature of the toxin-induced reactions ofhuman platelets has not yet
been delineated, but it appears probable that the toxin forms transmembrane pores,
and activation results from influx ofcalcium ions . The release of a granule constitu-
ents and ATP elicited by a toxin is not due to simple lysis of the platelets, since
no release of cytoplasmic LDH was noted even at 12.5 g,g/ml a toxin . This finding
fully confirms the early report of Siegel and Cohen (29), who registered rapid K+
and NAD-efflux from toxin-treated platelets in the absence of protein release . Elec--
tron microscopic studies are presently underway in this laboratory, and preliminary
results also indicate that platelet lysis does not occur at the given toxin concentra-
tions . Analogous, calcium-dependent cell activation after binding of pore-forming
cytolysins to membranes has been demonstrated in several recent studies . Examples
include the stimulation of arachidonate metabolism invoked by a toxin in endothelial
cells (23) and leukocytes (24), and by complement C5b-9 in various cell targets (e.g .
references 46-49) . With special regard to platelets, it is notable that earlier studies
by Polley and Nachman (50, 51), more recently followed up by Hansch et al . (52)
and Wiedmer and Sims (53, 54), have similarly demonstrated platelet activation
by C5b-9 . In our present study, toxin-induced activation unsurprisingly exhibited
a requirement for Cat+ , and release of PF4 by 2.5-12 gg/ml a toxin was totally
abrogated in the presence ofEDTA . Why PF4 release is apparently diminished when
platelets in citrated and EDTA-anticoagulated PRP are given high doses of toxin
(12.5 4g/ml) is unclear. We currently speculate that this may be due to rapid
codiffusion of citrate and EDTA across the toxin pores into the cells . The cause of
minimal PF-4 release observed in EDTA at marginal toxin levels (1 ~Lg/ml) also re-
mains unknown .
The failure of indomethacin and the thromboxane receptor blocker to suppress
platelet response to a toxin contrasts with the effects of these inhibitors on ADP-
dependent stimulation and indicates that the platelet response to a toxin bypasses
the cyclooxygenase/thromboxane pathway (36-38) . These preliminary results are
presented because the realization that the described processes are refractory towards
inhibition by related pharmacotherapeutic agents may be of practical importance .
From a positive viewpoint, a toxin could become valuable as a membrane-perme-BHAKDI ET AL.
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abilizing agent for probing the minimal requirements for granule exocytosis in platelets .
Several recent studies have already begun to exploit the use ofthis toxin in the study
of exocytic processes (e.g ., reference 55) . The toxin could also be used as a tool to
probe the importance ofthromboxane in the induction ofplatelet aggregation (56, 57) .
A priori, it may not be surprising that a cytolysin that generates transmembrane
pores stimulates platelets . The unexpected findings made in the present study relate
to the extreme susceptibility ofhuman platelets and the capacity of a toxin to evoke
procoagulatory responses in these cells in whole blood at low concentrations such
as may be expected to be present in tissues during severe infections with S. aureus
and systemic disease . In vitro, a toxin can reduce clotting times by up to 70%, an
effect that is dependent on the presence of platelets . In vivo, a toxin may thus act
synergistically with staphylocoagulase to cause local thrombus formation . In severe
deep infections and septicemia, systemic platelet responses to a toxin might even
contribute to the pathogenesis of disseminated intravascular coagulation . The present
study is a long overdue continuation of the pioneering work by Siegel and Cohen
(29) and Bernheimer and Schwartz (30) . It is the first demonstration that low, non-
hemolytic levels of a bacterial cytolysin can promote coagulation by selectively ac-
tivating platelets in human blood .
Staphylococcal a toxin in the nonhemolytic concentration range of-1 wg/ml binds
to and stimulates platelets in human blood . After addition of the toxin to stirred
platelet-rich plasma, a short lag-phase (30-70 s) is followed by platelet shape change
and irreversible aggregation . The stimulation of platelets in whole citrated or
heparinized blood has also been demonstrated by measurements of platelet factor
4 release . Aggregation and release of granule constituents are not inhibitable by in-
domethacin or by the thromboxane receptor blocker BM 13177 . Washed human
platelets are sensitive to even lower concentrations of 0.05-0.10 wg/ml a toxin . In
the presence ofhuman IgG antibodies, the threshold for effective toxin attack returns
to levels ofN1 pg/ml . An mAb that inhibits toxin binding to cells totally suppresses
platelet activation if preincubated, but not if applied simultaneously with the toxin .
Activation ofwashed platelets correlates with binding of toxin oligomers to the cells,
maximal activation occurring upon binding of an average of <100 hexamers per
platelet . When added to recalcified citrated blood or to platelet-rich plasma, a toxin
reduces clotting times by up to 70% ; this effect is dependent on the presence ofplatelets .
The collective data identify platelets as primary targets for a toxin attack in human
blood, and demask its potential to invoke imbalance of hemostasis that may be of
pathophysiological relevance during severe local and systemic staphylococcal infec-
tions in the human host .
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